EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study

Ozlem Yilmaz Nas, Catherine Ashmore, Sharon Evans iD, Alex Pinto, Anne Daly iD, Nurcan Yabancı Ayhan, Anita MacDonald

Nutrients · 2024

DOI: 10.3390/nu16142204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Ozlem Yilmaz Nas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Birmingham Children's Hospital, Birmingham B4 6NH, UK. Hauptthemen laut MEDLINE: Phenylketonurias, Infant Formula, Phenylalanine. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The long-term efficacy and use of phenylalanine-free infant amino acid formula (PFIF) is understudied. This retrospective, longitudinal study evaluated PFIF (PKU Start: Vitaflo International) in children with phenylketonuria, collecting data on metabolic control, growth, dietary intake, and symptoms and the child’s experience with PFIF. Twenty-five children (12 males, 48%) with a median age of 3.6 years (2.0–6.2 years) were included. During 24 months follow-up, children maintained normal growth and satisfactory metabolic control. The protein intake from protein substitutes increased from 2.7 at 6 months to 2.8 g/kg/day at 24 months, while natural protein decreased from 0.6 to 0.4 g/kg/day. By 24 months, most children (n = 16, 64%) had stopped PFIF, while nine (36%) continued with a median intake of 450 mL/day (Q1:300 mL, Q3: 560 mL). Children who continued PFIF after 24 months of age had higher energy and fat intakes with higher weight/BMI z-scores compared with those who stopped earlier (p < 0.05). Constipation was reported in 44% of infants but improved with age. Initial difficulty with PFIF acceptance was reported in 20% of infants but also improved with time. Prolonged use of PFIF in pre-school children may contribute to poor feeding patterns and overweight; thus, replacing the majority of the protein equivalent provided by PFIF with a weaning protein substitute by 12 months and discontinuing PFIF before 2 years is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylketonuriasInfant FormulaPhenylalanineHumansRetrospective StudiesMaleFemaleChild, PreschoolInfantChildLongitudinal StudiesDietary ProteinsConstipationEnergy Intake

Stichwörter der Autor:innen

growthinfancyinfant protein substitutemetabolic controlphenylketonuria

Substanzen

PhenylalanineDietary Proteins

Autor:innen und Institutionen

  • Birmingham Children's Hospital, Birmingham B4 6NH, UK.
  • Department of Nutrition and Dietetics, Ankara Yildirim Beyazit University, Ankara 06760, Turkey.
  • Department of Nutrition and Dietetics, Ankara University, Ankara 06760, Turkey.

ORCID-Profile: Sharon Evans, Anne Daly

Zitieren

APA

Yilmaz Nas, O., Ashmore, C., Evans, S., Pinto, A., Daly, A., Yabancı Ayhan, N., & MacDonald, A. (2024). Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study. Nutrients. https://doi.org/10.3390/nu16142204

Vancouver

Yilmaz Nas O, Ashmore C, Evans S, Pinto A, Daly A, Yabancı Ayhan N, et al. Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study. Nutrients. 2024. doi:10.3390/nu16142204

BibTeX
@article{YilmazNas2024,
  author = {Yilmaz Nas, Ozlem and Ashmore, Catherine and Evans, Sharon and Pinto, Alex and Daly, Anne and Yabancı Ayhan, Nurcan and MacDonald, Anita},
  title = {Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16142204}
}
Kostenlos starten →